The Board of Directors of Sopharma AD (the “Company”) hereby notifies that on 29 October 2012 was signed a merger agreement between Bulgarian Rose – Sevtopolis AD (merging company) and Sopharma AD (acquiring company). The agreement settles both the technical process of the merger of Bulgarian Rose – Sevtopolis AD into Sopharma AD, as well as the ensuing consequences for the two companies. The fair price of the shares of the companies involved in the transformation is determined based on generally accepted valuation methods.

The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 25 October 2012 up to and including 31 October 2012 the Company bought 162303 own shares representing 0.123% of the share capital of the Company, to the total value of BGN 382683.79 on the Bulgarian Stock Exchange. The average price per share was BGN 2.36.

The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.

Pursuant to art. 117, par. 2 of the Public Offering of Securities Act and art. 27, par. 5 of Ordinance № 2/17.09.2003 on the prospectuses for public offerings of securities and disclosure of information by public companies and other issuers of securities, please be informed that the Extraordinary General Meeting of shareholders of Sopharma AD, held on 01.11.2012 in Sofia, 16 Iliensko shousee, took the following decision:

The Board of Directors of Sopharma AD (the “Company”) notifies that for October 2012 Sopharma AD realized decrease of sales revenues of 2% compared to the same period of 2011, including 10% decrease of domestic sales and 2% increase of export sales.

During the first ten months of this year Sopharma AD realized an increase of sales revenues of 2%, including 10% decrease of domestic sales and 7% increase of export sales compared to the same period of 2011.

The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 8 November 2012 up to and including 14 November 2012 the Company bought 56111 own shares representing 0.043% of the share capital of the Company, to the total value of BGN 127209.75 on the Bulgarian Stock Exchange. The average price per share was BGN 2.27.

The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.

The Board of Directors of Sopharma AD (the “Company”) hereby notifies that on 21 November 2012 Sopharma AD received a notification of disclosure of shareholdings from Telso AD regarding the buying of 13,000 shares. After this transaction the share of Telso AD in the capital of Sopharma AD reached 5,0061%. The date of registration of the transaction with the Central Depository AD is 15 November 2012.

The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 15 November 2012 up to and including 21 November 2012 the Company bought 1471 own shares representing 0.0011% of the share capital of the Company, to the total value of BGN 3238.58 on the Bulgarian Stock Exchange. The average price per share was BGN 2.20.

The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.

The Board of Directors of Sopharma AD (the “Company”) hereby notifies that on 26 November 2012 Sopharma AD received a notification of disclosure of shareholdings from Telso AD regarding the selling of 35,000 shares. After this transaction the share of Telso AD in the capital of Sopharma AD decreased to 4,979%.

The date of registration of the transaction with the Central Depository AD is 26 November 2012.

The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 22 November 2012 up to and including 28 November 2012 the Company bought 6010 own shares representing 0.0045% of the share capital of the Company, to the total value of BGN 13230.96 on the Bulgarian Stock Exchange. The average price per share was BGN 2.20.

The Board of Directors of Sopharma AD (the “Company”) notifies that for November 2012 sales revenues remained at the same level compared to the same period of 2011, including 1% increase of export sales and no changes in domestic sales.

During the first eleven months of this year Sopharma AD recorded an increase of sales revenues of 2%, including 9% decrease of domestic sales and 6% increase of export sales compared to the same period of 2011.